Panitumumab

Common brands: Vectibix, Tolak, Efudex, Fluorouracil, Oxaliplatin

Top reporter: Amgen, Inc

Epidermal Growth Factor Receptor Antagonist [EPC]Nucleoside Metabolic Inhibitor [EPC]Platinum-based Drug [EPC]Vascular Endothelial Growth Factor Inhibitor [EPC]Corticosteroid [EPC]
14,906
Total Reports
6,412
Serious Reports
2,467
Death Reports
30
Reported Reactions
Death Report Ratio: High (16.55%)

Patient Demographics

Male
7,767
Female
4,650

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Panitumumab.

# Reaction Reports % of Total
1 RASH 1,769
8.9%
2 DIARRHOEA 1,550
7.8%
3 DERMATITIS ACNEIFORM 1,020
5.1%
4 DEATH 922
4.6%
5 NEUTROPENIA 900
4.5%
6 SKIN TOXICITY 865
4.3%
7 HYPOMAGNESAEMIA 812
4.1%
8 NAUSEA 790
4.0%
9 DISEASE PROGRESSION 711
3.6%
10 NEUROPATHY PERIPHERAL 700
3.5%
11 COLORECTAL CANCER METASTATIC 664
3.3%
12 FATIGUE 640
3.2%
13 OFF LABEL USE 624
3.1%
14 VOMITING 607
3.0%
15 STOMATITIS 579
2.9%
16 DRY SKIN 568
2.8%
17 PARONYCHIA 568
2.8%
18 THROMBOCYTOPENIA 564
2.8%
19 DECREASED APPETITE 538
2.7%
20 ASTHENIA 537
2.7%
21 ANAEMIA 502
2.5%
22 PYREXIA 492
2.5%
23 THERAPY PARTIAL RESPONDER 449
2.2%
24 ERYTHEMA 410
2.1%
25 PRURITUS 410
2.1%
26 METASTASES TO LIVER 407
2.0%
27 INTERSTITIAL LUNG DISEASE 375
1.9%
28 DYSPNOEA 357
1.8%
29 RASH PUSTULAR 317
1.6%
30 MUCOSAL INFLAMMATION 316
1.6%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.